278 related articles for article (PubMed ID: 34966712)
21. Cost-effectiveness analysis of systematic fast-track transition from oncological treatment to specialised palliative care at home for patients and their caregivers: the DOMUS trial.
Halling CMB; Wolf RT; Sjøgren P; Von Der Maase H; Timm H; Johansen C; Kjellberg J
BMC Palliat Care; 2020 Sep; 19(1):142. PubMed ID: 32933489
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
23. Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
Lin Z; Zhang L; Yang X; Liu L; Xuan J
J Med Econ; 2020 Jun; 23(6):659-666. PubMed ID: 31999196
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care).
Maru S; Byrnes J; Carrington MJ; Chan YK; Thompson DR; Stewart S; Scuffham PA;
Int J Cardiol; 2015 Dec; 201():368-75. PubMed ID: 26310979
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
26. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
Theriou C; Fielden CA; Kitterick PT
Ear Hear; 2019; 40(6):1425-1436. PubMed ID: 30998548
[TBL] [Abstract][Full Text] [Related]
27. Care Management to Reduce Disparities and Control Hypertension in Primary Care: A Cost-effectiveness Analysis.
Hong JC; Padula WV; Hollin IL; Hussain T; Dietz KB; Halbert JP; Marsteller JA; Cooper LA
Med Care; 2018 Feb; 56(2):179-185. PubMed ID: 29239999
[TBL] [Abstract][Full Text] [Related]
28. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
[TBL] [Abstract][Full Text] [Related]
29. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
[TBL] [Abstract][Full Text] [Related]
30. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
Front Public Health; 2022; 10():942800. PubMed ID: 35923949
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model.
Li H; Li G; Li N; Liu C; Yuan Z; Gao Q; Hao S; Fan S; Yang J
PLoS One; 2023; 18(11):e0291390. PubMed ID: 37971984
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of habit-based advice for weight control versus usual care in general practice in the Ten Top Tips (10TT) trial: economic evaluation based on a randomised controlled trial.
Patel N; Beeken RJ; Leurent B; Omar RZ; Nazareth I; Morris S
BMJ Open; 2018 Aug; 8(8):e017511. PubMed ID: 30104307
[TBL] [Abstract][Full Text] [Related]
34. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
Goyal A; Murray JM
Clin Drug Investig; 2016 Aug; 36(8):637-48. PubMed ID: 27166628
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of a multidisciplinary co-management program for the older hip fracture patients in Beijing.
Peng K; Yang M; Tian M; Chen M; Zhang J; Wu X; Ivers R; Si L
Osteoporos Int; 2020 Aug; 31(8):1545-1553. PubMed ID: 32219498
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of initial nonoperative management versus emergency laparoscopic appendectomy for acute complicated appendicitis.
Sugiura K; Suzuki K; Umeyama T; Omagari K; Hashimoto T; Tamura A
BMC Health Serv Res; 2020 Nov; 20(1):1019. PubMed ID: 33167993
[TBL] [Abstract][Full Text] [Related]
38. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
39. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of acupuncture compared with usual care for acute non-specific low back pain: secondary analysis of a randomised controlled trial.
Skonnord T; Fetveit A; Skjeie H; Brekke M; Grotle M; Klovning A; Aas E
Acupunct Med; 2022 Apr; 40(2):123-132. PubMed ID: 34847780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
